(IN BRIEF) A study by the Technical University of Munich and Harvard Medical School has shown that obesity drugs semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro) reduce the risk of hospitalization or death in patients with heart failure with preserved ejection … Read the full press release
Posted in Business, Education, Financial, Germany, Government, Healthcare, Industrial, Investment, Management, Marketing, News, Science, Technology
Tagged cardiovascular disease, Diabetes, German Heart Center, Harvard Medical School, Health Data Utilization Act, heart failure, heart failure with preserved ejection fraction, Heribert Schunkert, HFpEF, hospitalization, JAMA, mortality reduction, Mounjaro, Nils Krüger, obesity drugs, Ozempic, partnership, Semaglutide, Technical University of Munich, tirzepatide, TUM, Wegovy
(IN BRIEF) Research presented at ESC Congress 2025 has shown that GLP-1 receptor agonists, used to treat patients with heart failure and preserved ejection fraction, not only reduce hospitalizations and improve outcomes but also cut the environmental footprint of healthcare. … Read the full press release
Posted in Business, Environment, Financial, France, Government, Healthcare, Industrial, Investment, Management, Marketing, Media, News, Science, Spain, Technology
Tagged carbon footprint of healthcare, environmental co-benefits, ESC Congress 2025, European Society of Cardiology, FLOW trial, GLP-1 receptor agonists, greenhouse gas emissions, healthcare sustainability, heart failure with preserved ejection fraction, HFpEF, Lahey Hospital & Medical Center, medical waste reduction, Sarju Ganatra, SELECT Trial, STEP HFpEF, Sustain Health Solutions, sustainability, Sustainable Healthcare
EuropaWire (EW) is the first truly pan-European and leading press release distribution and newswire service for Europe and the European Union working towards consolidating Europe’s voice on the global newswire and media scene. The newswire service comes with advanced submission forms, flexible pricing and PR budgeting, granular targeting, nearly uncapped reach across countries, markets, verticals, industries, audiences, languages, etc., translation and localisation for greater local PR impact, in-depth distribution reporting, metrics and insights including measured PR reach, reads, engagements, impact, etc., no cap on words, images and multimedia to go along with your release, among others. Your press releases will be seen among the releases of Europe’s biggest and most prominent companies, brands and institutions. Here you can learn more about EuropaWire’s mission, achievements, services, etc.
HOW TO GET STARTED?